BTIG analyst Ryan Zimmerman lowered the firm’s price target on Intuitive Surgical (ISRG) to $574 from $616 and keeps a Buy rating on the shares as part of a broader research name on Medical Technology. The firm is updating its models to reflect the CMS having announced its proposed rule for the FY27 inpatient prospective payment system which includes, among other things, preliminary commentary and decisions regarding new technology add-on payments, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical price target lowered to $480 from $550 at Evercore ISI
- Private Markets: Kraken pauses IPO plans, Quince raises $500M
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors
- Intuitive Surgical: Stapler Reload Recall Seen as Contained, Buy Rating Reaffirmed
- Intuitive Surgical recalls curved-tip surgical staplers, says FDA